2.62
price up icon5.22%   0.13
after-market Dopo l'orario di chiusura: 2.60 -0.02 -0.76%
loading
Precedente Chiudi:
$2.49
Aprire:
$2.52
Volume 24 ore:
193.74K
Relative Volume:
0.60
Capitalizzazione di mercato:
$135.68M
Reddito:
$44.12M
Utile/perdita netta:
$-156.25M
Rapporto P/E:
-0.8534
EPS:
-3.07
Flusso di cassa netto:
$-154.61M
1 W Prestazione:
+4.38%
1M Prestazione:
-9.34%
6M Prestazione:
-46.75%
1 anno Prestazione:
-34.66%
Intervallo 1D:
Value
$2.47
$2.705
Intervallo di 1 settimana:
Value
$2.41
$2.76
Portata 52W:
Value
$2.345
$6.40

2 Seventy Bio Inc Stock (TSVT) Company Profile

Name
Nome
2 Seventy Bio Inc
Name
Telefono
339-499-9300
Name
Indirizzo
60 BINNEY STREET, CAMBRIDGE
Name
Dipendente
425
Name
Cinguettio
Name
Prossima data di guadagno
2024-12-12
Name
Ultimi documenti SEC
Name
TSVT's Discussions on Twitter

Confronta TSVT con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
TSVT
2 Seventy Bio Inc
2.62 135.68M 44.12M -156.25M -154.61M -3.07
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
438.40 113.67B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
683.08 74.97B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
665.68 40.50B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
277.16 35.95B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
120.88 29.63B 3.30B -501.07M 1.03B -2.1146

2 Seventy Bio Inc Stock (TSVT) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-06-06 Downgrade Goldman Neutral → Sell
2024-01-31 Aggiornamento Leerink Partners Market Perform → Outperform
2024-01-31 Downgrade TD Cowen Outperform → Market Perform
2023-10-30 Downgrade Leerink Partners Outperform → Market Perform
2023-10-12 Iniziato Citigroup Buy
2023-09-13 Downgrade Goldman Buy → Neutral
2023-09-12 Downgrade Guggenheim Buy → Neutral
2023-07-28 Downgrade Morgan Stanley Overweight → Equal-Weight
2022-10-31 Iniziato Guggenheim Buy
2022-05-02 Iniziato Goldman Buy
2022-02-10 Iniziato SVB Leerink Outperform
2022-01-06 Iniziato Cowen Outperform
2021-11-09 Iniziato Canaccord Genuity Buy
2021-11-08 Iniziato Morgan Stanley Overweight
2021-11-08 Iniziato Wedbush Outperform
Mostra tutto

2 Seventy Bio Inc Borsa (TSVT) Ultime notizie

pulisher
Jan 24, 2025

Layoff Tracker: Biogen to Cut Undisclosed Number of Research Employees - BioSpace

Jan 24, 2025
pulisher
Jan 20, 2025

Weiss Ratings Reaffirms “Sell (E+)” Rating for 2seventy bio (NASDAQ:TSVT) - Defense World

Jan 20, 2025
pulisher
Jan 04, 2025

Barclays PLC Sells 132,019 Shares of 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World

Jan 04, 2025
pulisher
Dec 18, 2024

Fmr LLC Has $701,000 Stock Holdings in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World

Dec 18, 2024
pulisher
Nov 15, 2024

Analysts Have Been Trimming Their 2seventy bio, Inc. (NASDAQ:TSVT) Price Target After Its Latest Report - Simply Wall St

Nov 15, 2024
pulisher
Nov 12, 2024

2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress - Business Wire

Nov 12, 2024
pulisher
Nov 06, 2024

Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results - GlobeNewswire

Nov 06, 2024
pulisher
Nov 04, 2024

2seventy bio to Report Third Quarter 2024 Financial Results and Participate in Upcoming Investor Conference - Business Wire

Nov 04, 2024
pulisher
Oct 22, 2024

2seventy bio, Inc. (NASDAQ:TSVT) Shares Sold by Exchange Traded Concepts LLC - Defense World

Oct 22, 2024
pulisher
Oct 17, 2024

BioAegis Therapeutics Enrolls First Patient in Phase 2 Clinical Trial of Gelsolin, an Immune Regulator, for the Treatment of Acute Respiratory Distress Syndrome (ARDS) - Yahoo Finance

Oct 17, 2024
pulisher
Oct 14, 2024

Dimensional Fund Advisors LP Sells 24,371 Shares of 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World

Oct 14, 2024
pulisher
Oct 09, 2024

TSVT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into 2seventy bio, Inc. and Encourages Investors to Contact the Firm - GlobeNewswire Inc.

Oct 09, 2024
pulisher
Sep 27, 2024

BMS and 2seventy bio Axe Trial for Ide-Cel in Newly Diagnosed Multiple Myeloma - CGTLive™

Sep 27, 2024
pulisher
Sep 25, 2024

2seventy bio Provides Update on KarMMa-9 Study and Previews Anticipated Strong Third Quarter Revenue Performance - Business Wire

Sep 25, 2024
pulisher
Sep 24, 2024

Seven Eight Capital LP Makes New $197,000 Investment in Beyond, Inc. (NYSE:BYON) - Defense World

Sep 24, 2024
pulisher
Sep 24, 2024

Q&A: Athens legends Five Eight and the makers of their new documentary film, "Weirdo" - Online Athens

Sep 24, 2024
pulisher
Sep 22, 2024

Four killed, dozens injured in Alabama mass shooting - Daily Sun

Sep 22, 2024
pulisher
Sep 22, 2024

Seven Eight Capital LP Sells 536 Shares of Dell Technologies Inc. (NYSE:DELL) - Defense World

Sep 22, 2024
pulisher
Sep 22, 2024

Four dead, 17 others shot in Birmingham mass shooting - WJLA

Sep 22, 2024
pulisher
Sep 22, 2024

Five Below, Inc. (NASDAQ:FIVE) Stake Raised by Teca Partners LP - Defense World

Sep 22, 2024
pulisher
Sep 22, 2024

Four killed, over 20 injured in Birmingham, Alabama shooting - Thaiger World

Sep 22, 2024
pulisher
Sep 22, 2024

At least four dead and dozens injured in shootout with multiple assailants in the United States - Top Buzz Times

Sep 22, 2024
pulisher
Sep 22, 2024

Four people dead and dozens injured in US mass shooting horror - Express

Sep 22, 2024
pulisher
Sep 21, 2024

Analyst bullish on Tectonic's TX45 ahead of full trial results presentation at AHA - Investing.com India

Sep 21, 2024
pulisher
Sep 19, 2024

Tectonic Therapeutic Announces Favorable Phase 1a Safety, Tolerability and PK/PD Results for Lead Program TX45 - GlobeNewswire

Sep 19, 2024
pulisher
Sep 19, 2024

Hedge fund Two Sigma in settlement talks with US SEC, WSJ reports - XM

Sep 19, 2024

2 Seventy Bio Inc Azioni (TSVT) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

2 Seventy Bio Inc Azioni (TSVT) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Snow Jessica
See Remarks
Jan 03 '25
Sale
2.94
1,000
2,936
152,479
Snow Jessica
See Remarks
Jan 07 '25
Sale
2.64
186
491
147,179
Leschly Nick
Director
Jan 03 '25
Sale
2.94
85,978
252,423
1,234,498
Leschly Nick
Director
Jan 06 '25
Sale
2.78
892
2,478
1,233,606
Eatwell Victoria
Chief Financial Officer
Jan 03 '25
Sale
2.94
1,013
2,974
339,076
Eatwell Victoria
Chief Financial Officer
Jan 06 '25
Sale
2.78
97
270
338,979
Baird William D III
President and CEO
Jan 03 '25
Sale
2.94
31,718
93,121
862,889
Baird William D III
President and CEO
Jan 06 '25
Sale
2.78
763
2,120
862,126
Snow Jessica
See Remarks
Dec 13 '24
Sale
3.23
2,287
7,393
153,479
$352.30
price down icon 5.49%
$41.04
price up icon 0.79%
$22.36
price up icon 3.33%
$5.41
price up icon 3.84%
biotechnology ONC
$226.89
price up icon 0.08%
$120.88
price down icon 0.23%
Capitalizzazione:     |  Volume (24 ore):